Syntara Limited · ASX:SNT

Syntara — European Hematology Association Congress 2025

21 slides from Syntara's conference presentation, Jun 13, 2025

  1. Slide 1: EHA 2025: SNT-5505 Interim Data

    For personal use only ™ EHA 2025: SNT-5505 Interim Data Gary Phillips, CEO 13th June 2025

  2. Slide 2: Forward looking statement

    Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau

  3. Slide 3: Myelofibrosis

    Myelofibrosis A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells For personal use only Myelofibrosis characterised by a build up of scar tissue (fibrosis) in Key Facts bone marrow and abnormal proliferation of blood precursor cells reducing the production of

  4. Slide 4: Myelofibrosis: Limited treatment options currently

    Myelofibrosis Limited treatment options currently Current standard of care (SoC): JAK inhibitors For personal use only SNT-5505 Key• Class Factsof drugs used in the management of splenomegaly In contrast to SoC, SNT-5505 intervenes at the source, (enlarged spleen) and other constitutional symptoms c

  5. Slide 5: Lysyl Oxidases in Myelofibrosis: Structural effects

    Lysyl Oxidases in Myelofibrosis SNT-5505 designed to improve the bone marrow microenvironment  Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways1 Structural effe

  6. Slide 6: Lysyl Oxidases in Myelofibrosis: Signalling effects

    Lysyl Oxidases in Myelofibrosis SNT-5505 designed to improve the bone marrow microenvironment  Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways1 Signalling effe

  7. Slide 7: Lysyl Oxidases in Myelofibrosis

    Lysyl Oxidases in Myelofibrosis SNT-5505 designed to improve the bone marrow microenvironment  Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways1 Structural effe

  8. Slide 8: Lysyl Oxidases in Myelofibrosis: multi-faceted mode of action

    Lysyl Oxidases in Myelofibrosis SNT-5505 designed to improve the bone marrow microenvironment  Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients; For personal use only increased lysyl oxidase activity adversely impacts BM health in several ways1 SNT-5505 has a

  9. Slide 9: SNT-5505 Trial: Add-On

    SNT-5505 Trial: Add-On SNT-5505-MF-101 Add-on to RUX (study in progress, NCT4676529)  This add-on phase aims to further evaluate the safety and efficacy of SNT-5505 For personal use only (200 mg BID) in patients with MF on stable background regimens of ruxolitinib (RUX) over a 52-week period STUDY

  10. Slide 10: Baseline Characteristics

    Baseline Characteristics Heterogenous population with a high disease burden For personal use only  Patients (pts) in the trial had been on RUX for Characteristic N=16 an average of three years, with symptom Age, median (range), years 71 (46-82) scores, spleen sizes and blood counts Sex, male, n (%)

  11. Slide 11: Safety

    Safety SNT-5505 has been well tolerated with no treatment related SAEs Pts with Grade 3/4 TEAEs Regardless of Causality** For personal use only  Majority of treatment emergent AEs were mild, 63/84 (75%) ≤ Grade 2 Grade 3 Grade 4 Adverse Event N=16 N=16  76% (64/84) of TEAEs considered not Anemia 4

  12. Slide 12: Hematology

    Hematology Stable with some changes consistent with minor anemia response 150 For personal use only  At baseline: Hemoglobin g/L 100  2 were transfusion dependent (TD)  7 were transfusion requiring (TR) 50  7 were transfusion independent (TI)  During treatment: 0 1 4 12 18 24 38 52  Hemoglobin

  13. Slide 13: Total Symptom Score

    Total Symptom Score 73% (8/11) of patients achieved TSS50 at Week 24 or beyond Reduction at W24 Additional reduction past W24 For personal use only  At Week 24 # Pt completed W52 and study * Pt reached W38 and is ongoing  Median absolute change -6 Baseline TSS (range -2 to -20) 37 10 52# 32 11* 18

  14. Slide 14: Spleen Volume Reduction

    Spleen Volume Reduction 44% (4/9) of patients achieved SVR25 at Week 24 or beyond Reduction at W24 For personal use only Additional reduction past W24  At Week 24 # Pt completed W52 and study * Pt reached W38 and is ongoing  2/11 pts not evaluable for SVR 20 Baseline Spleen Volume (cm3) (SV < 450

  15. Slide 15: Interim Data Summary

    Interim Data Summary SNT-5505 promising as an add-on to RUX in a sub-optimal setting TSS change over time – completed patients (N=5) For personal use only  Safe and well tolerated with no changes in dose of concomitant RUX* Week 0 12 24 38 52  Robust and sustained high target engagement throughout

  16. Slide 16: Competitive Landscape

    Competitive Landscape Comparable open label Phase 2 studies for drugs under development Latest Phase 2 Open Label Trial results in Suboptimal Patient Population For personal use only Drug Program Baseline Characteristics Safety Status N TSS50 SVR25 SVR35 (median, range) Grade 3/4 events ≥ 10% P3 naï

  17. Slide 17: Strong interest in MF assets from strategics

    Strong interest in MF assets from strategics Target / Acquiror / / / / For personal use only Date of Announcement Dec-2024 Feb-2024 June-2023 July-2022 Drug Name Elritercept Pelabresib Pacritinib Momelotinib Lead Indication / MDS and MF Myelofibrosis Myelofibrosis Myelofibrosis Phase (at transaction

  18. Slide 18: Conclusions

    Conclusions Interim data1 suggests that SNT-5505 combined with ruxolitinib may deliver deep and long-lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone For personal use only Consistent with Despite the relatively Reductions in Remaining 3 patients monotherapy data2, sm

  19. Slide 19: Targeting Multiple Near Term Opportunities in High Value Markets

    Targeting Multiple Near Term Opportunities in High Value Markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 12 month data Myelofibrosis Phase 2 ~$1 billion1 June 2025 SNT-5505 Myelodysplastic Syndrome Low & intermediate Risk

  20. Slide 20: Recent & Anticipated News Flow

    Recent & Anticipated News Flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only Key Event COMPLETED Q1 2025 June 2025 Q2 2025 Mid 2025 • Latest phase 2a Q4 2024 9/12 month SNT-5505 Phase 2a Syntara skin • FDA grants Fast Track

  21. Slide 21: Gary Phillips, Chief Executive Officer

    For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au

Syntara — European Hematology Association Congress 2025 on 6ix